CAJ | 학술논문

目的：比较宫颈癌组织和Hela细胞株中多种恶性肿瘤的侧群（SP）细胞的含量和生物学特性。方法采用Altra流式细胞仪分选出宫颈癌组织原代培养6代细胞和Hela细胞株中SP细胞，检测两种细胞的表面标记和细胞周期增殖状况。结果宫颈癌组织和Hela细胞株中SP细胞水平分别为（1．62±0．48）％和（2．70±0．59）％，Hela细胞株中SP的水平明显高于宫颈癌组织，差异有统计学意义（P＜0．05）。宫颈癌组织和Hela细胞株SP细胞的生物学标记（ABCG2、CD133、CD43、P63、Ki‐67、MDR）表达率分别为：ABCG2（78．59±5．42）％vs．（80．17±3．60）％，CD133（51．55±6．29）％vs．（52．87±4．96）％，CD43（69．73±5．70）％vs．（70．68±5．44）％，P63（47．56±6．92）％vs．（48．06±5．28）％，Ki‐67（14．69±1．69）％vs．（15．33±1．38）％，MDR（58．36±11．12）％vs．（58．24±5．32）％，表达差异均无统计学意义（P＞0．05）。各细胞周期时相分布分别为：G0/G1期（94．70±1．76）％vs．（95．10±1．59）％，S期（3．25±0．99）％vs．（2．92±0．84）％，G2/M期（2．05±1．10）％vs．（1．98±0．95）％，凋亡率（4．06±0．64）％vs．（3．92±0．59）％，坏死率（1．00±0．38）％vs．（1．12±0．31）％，表达差异均无统计学意义（P＞0．05）。宫颈癌组织和Hela细胞株两组SP细胞在生物学标记和细胞周期增殖状况的表达差异均无统计学意义（P＞0．05）。结论宫颈癌组织和Hela细胞株中都存在SP细胞且含量不同，他们均具有肿瘤干细胞的生物学特性。
목적：비교궁경암조직화Hela세포주중다충악성종류적측군（SP）세포적함량화생물학특성。방법채용Altra류식세포의분선출궁경암조직원대배양6대세포화Hela세포주중SP세포，검측량충세포적표면표기화세포주기증식상황。결과궁경암조직화Hela세포주중SP세포수평분별위（1．62±0．48）％화（2．70±0．59）％，Hela세포주중SP적수평명현고우궁경암조직，차이유통계학의의（P＜0．05）。궁경암조직화Hela세포주SP세포적생물학표기（ABCG2、CD133、CD43、P63、Ki‐67、MDR）표체솔분별위：ABCG2（78．59±5．42）％vs．（80．17±3．60）％，CD133（51．55±6．29）％vs．（52．87±4．96）％，CD43（69．73±5．70）％vs．（70．68±5．44）％，P63（47．56±6．92）％vs．（48．06±5．28）％，Ki‐67（14．69±1．69）％vs．（15．33±1．38）％，MDR（58．36±11．12）％vs．（58．24±5．32）％，표체차이균무통계학의의（P＞0．05）。각세포주기시상분포분별위：G0/G1기（94．70±1．76）％vs．（95．10±1．59）％，S기（3．25±0．99）％vs．（2．92±0．84）％，G2/M기（2．05±1．10）％vs．（1．98±0．95）％，조망솔（4．06±0．64）％vs．（3．92±0．59）％，배사솔（1．00±0．38）％vs．（1．12±0．31）％，표체차이균무통계학의의（P＞0．05）。궁경암조직화Hela세포주량조SP세포재생물학표기화세포주기증식상황적표체차이균무통계학의의（P＞0．05）。결론궁경암조직화Hela세포주중도존재SP세포차함량불동，타문균구유종류간세포적생물학특성。
Objective To compare the proportion and biological characteristics of side population cells between human cervical cancer and Hela cells .Methods Altra flow cytometry was used to isolate SP cells from human cervical cancer and Hela cells ,the cells markers and cell cycles were measured .Results The proportions of SP cells in human cervical cancer and Hela cells were (1 .62 ± 0 .48)% and (2 .70 ± 0 .59)% ,the percentage of SP in Hela cells were significantly higher than in human cervical cancer (P<0 .05) .The proportions of ABCG2 ,CD133 ,CD43 ,P63 ,Ki‐67 ,MDR were (78 .59 ± 5 .42)% vs .(80 .17 ± 3 .60)% ,(51 .55 ± 6 .29% )vs .(52 .87 ± 4 .96)% ,(69 .73 ± 5 .70)% vs .(70 .68 ± 5 .44) ,(47 .56 ± 6 .92)% vs .(48 .06 ± 5 .28)% ,(14 .69 ± 1 .69)% vs . (15 .33 ± 1 .38)% ,(58 .36 ± 11 .12)% vs .(58 .24 ± 5 .32)% in human cervical cancer and Hela cells ,respectively (P>0 .05) .The proportions of G0/G1 ,S ,G2/M were (94 .70 ± 1 .76)% vs .(95 .10 ± 1 .59)% ,(3 .25 ± 0 .99)% vs .(2 .92 ± 0 .84)% ,(2 .05 ± 1 .10)%vs .(1 .98 ± 0 .95)% ,respectively .The proportions of apoptosis and necrosis were (4 .06 ± 0 .64)% vs .(3 .92 ± 0 .59)% ,(1 .00 ± 0 .38)% vs .(1 .12 ± 0 .31)% .There were no significant differences in biological characteristics ,cell cycle or cell apoptosis of the two SP cells between human cervical cancer and Hela cells(P> 0 .05) .Conclusion Side population cells express in human cervical cancer and Hela cells ,and percentages of the two SP cells are different .The two SP cells have the characteristics of cancer stem cells .So it can be viewed as the pointcut to research the cervical cancer stem cell and supply scientific basis to identify the cervical cancer stem cell .